SCHEMBL4748831

SCHEMBL4748831

CCNC1(C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13826336 0.88
SCHEMBL22044790 0.85 DPP4 (0.36)
SCHEMBL21363994 0.85 DPP4 (0.36)
SCHEMBL5258960 0.85 DPP4 (0.36)
SCHEMBL5260452 0.85 DPP4 (0.36)
SCHEMBL23764033 0.81 GRIN2D (0.33)
SCHEMBL22142926 0.81 OPRL1 (0.36)
SCHEMBL20715149 0.79 CHRM2 (0.32)
SCHEMBL1691932 0.79 GRIN2D (0.32)
SCHEMBL25105659 0.77 KDM4E (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116731046-B High-activity HPK1 kinase inhibitor 杭州阿诺生物医药科技有限公司 2025-06-03 CN disclosed
CN-114555565-B Nitrogen-containing heterocyclic compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-03-05 CN disclosed
US-20230399327-A1 HIGH ACTIVITY HPK1 KINASE INHIBITOR ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2023-12-14 US disclosed
CN-117024445-A Compounds for preparing HPK1 kinase inhibitor and synthesis method thereof 杭州阿诺生物医药科技有限公司 2023-11-10 CN disclosed
CN-116731046-A High-activity HPK1 kinase inhibitor 杭州阿诺生物医药科技有限公司 2023-09-12 CN disclosed
CN-116685585-A High-activity HPK1 kinase inhibitor 杭州阿诺生物医药科技有限公司 2023-09-01 CN disclosed
CN-114555565-A Nitrogen-containing heterocyclic compound, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2022-05-27 CN disclosed
WO-2022089398-A1 HIGH ACTIVITY HPK1 KINASE INHIBITOR 杭州阿诺生物医药科技有限公司 2022-05-05 WO disclosed
WO-2021114691-A1 NITROGEN-CONTAINING RING-FUSED COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2021-06-17 WO disclosed
US-10815246-B2 Thailanstatin analogs PH PHARMA CO., LTD. (KR) 2020-10-27 US disclosed
US-20190233430-A1 THAILANSTATIN ANALOGS PH PHARMA CO., LTD. (KR) 2019-08-01 US disclosed
WO-2015095953-A1 SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2015-07-02 WO disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed